HARLEY-DAVIDSON, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HARLEY-DAVIDSON, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.47B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.19B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.84B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $5.76B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $5.34B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $4.05B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $5.36B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $5.72B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $5.65B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $6.00B | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.60B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.88B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.93B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $4.54B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $3.26B | Feb 24, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $338.74M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $455.36M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $706.59M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $741.41M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $650.02M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.30M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $423.64M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $531.45M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $521.76M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $692.16M | Feb 28, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $386.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $416.63M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $779.08M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $909.28M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $823.44M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $9.68M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $555.61M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $713.52M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $882.08M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $1.05B | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $159.30M | Feb 23, 2024 |
| FY2023 | Dec 31, 2022 | $158.60M | Feb 23, 2024 |
| FY2023 | Dec 31, 2021 | $175.10M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $202.40M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $216.50M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $191.60M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $175.20M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $172.30M | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $161.20M | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $138.30M | Feb 21, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.18B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.08B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.05B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.05B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $1.20B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.26B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $1.18B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $1.21B | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $568.92M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $754.89M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $548.46M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $975.70M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.18B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $868.27M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.21B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $1.01B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $1.17B | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.68M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $196.56M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $207.40M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $151.67M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $120.18M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $131.05M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $181.44M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $213.52M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $206.29M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $256.26M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.04B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $11.88B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $12.14B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $11.49B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $11.05B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $12.01B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $10.53B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $10.67B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $9.97B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $9.89B | Feb 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.14B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.17B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.25B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $2.90B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.55B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.72B | Feb 25, 2022 |
| FY2021 | Dec 31, 2019 | $1.80B | Feb 25, 2022 |
| FY2021 | Dec 31, 2018 | $1.77B | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $1.84B | Feb 23, 2021 |
| FY2019 | Dec 31, 2016 | $1.92B | Feb 19, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $61.66M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $62.70M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $62.09M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $63.18M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $65.98M | Feb 24, 2023 |
| FY2020 | Dec 31, 2019 | $64.16M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $55.05M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $55.95M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $53.39M | Feb 21, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.72B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.47B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.10B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $2.49B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.84B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.28B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.19B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.01B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.61B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.34B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.09B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.59B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.53B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.43B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.87B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $3.26B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $833.87M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.20B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $687.52M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $759.98M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.47B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.32B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.25B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $6.14B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $6.14B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $7.97B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $6.87B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $6.46B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $5.71B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $5.75B | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 19, 2020 |
| FY2019 | Sep 29, 2019 | 0 | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 19, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 19, 2020 |
| FY2019 | Sep 29, 2019 | 0 | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 19, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 111.66M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 124.28M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 136.31M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 145.86M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 153.57M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 152.93M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 152.47M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | 159.66M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 168.10M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 175.90M | Feb 21, 2018 |